Prevention of complications of colonic diverticular disease in outpatient practice


Cite item

Full Text

Abstract

The literature review gives an update on the frequency and risk factors of complications of colonic diverticular disease, the results of recent investigations, which suggest the success and safety of outpatient treatment for uncomplicated acute diverticulitis. It evaluates the efficacy of pharmacological agents from different groups in preventing complications of colonic diverticular disease.

References

  1. Viniol A, Keunecke C, Biroga T, Stadje R, Dornieden K, Bösner S, Donner-Banzhoff N, Haasenritter J, Becker A Studies of the symptom abdominal pain — a systematic review and meta-analysis. Fam Pract. 2014;31(5):517-529. doi: 10.1093/fampra/cmu036.
  2. Kang JY, Firwana B, Green AE et al. Uncomplicated diverticular disease is not a common cause of colonic symptoms. Aliment Pharmacol Ther. 2011;33(4):487-494.
  3. Delvaux M. Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. Aliment Pharmacol Ther. 2003;18(Suppl. 3):71-74. doi: 10.1046/j.0953-0673.2003.01720.x.
  4. Lazebnik L, Baryshnikov E, Parfenov A, Prilepskaja S, Kosacheva T. First results of epidemiological study MUZe (prevalence of colon diverticulosis, colorectal polips and colorectal cancer among adult population of Moscow with chronic constipation and alarm symptoms). Scandinavian J Gastroent. 2010;45(Suppl. 247):86.
  5. Stollman NH, Morgan R et al. Hospitalisations for diverticular disease. Effects of age on presentation. Am J Gastroenterol. 1999;11:3110-3121.
  6. Jamal Talabani A, Lydersen S, Endreseth BH, Edna TH. Major increase in admission- and incidence rates of acute colonic diverticulitis. Int J Colorectal Dis. 2014;29(8):937-945. doi: 10.1007/s00384-014-1888-9.
  7. Humes DJ, Spiller RC. Review article: The pathogenesis and management of acute colonic diverticulitis. Aliment Pharmacol Ther. 2014;39(4):359-370. doi: 10.1111/apt.12596.
  8. Jackson JD, Hammond T. Systematic review: outpatient management of acute uncomplicated diverticulitis. Int J Colorectal Dis. 2014;29(7):775-781. doi: 10.1007/s00384-014-1900-4.
  9. Tursi A. Efficacy, safety, and applicability of outpatient treatment for diverticulitis. Drug Healthc PatientSaf. 2014;6:29-36. doi: 10.2147/dhps.s61277.
  10. Morris AM, Regenbogen SE, Hardiman KM, Hendren S Sigmoid diverticulitis: a systematic review. JAMA. 2014;311(3):287-297. doi: 10.1001/jama.2013.282025.
  11. Edna TH, Jamal Talabani A, Lydersen S, Endreseth BH. Survival after acute colon diverticulitis treated in hospital. Int J Colorectal Dis. 2014;29(11):1361-1367. doi: 10.1007/s00384-014-1946-3.
  12. Dobbins C, Defontgalland D, Duthie G, Wattchow DA. The relationship of obesity to the complications of diverticular disease. Colorectal Dis. 2006;8(1):37-40.
  13. Jeong JH, Lee HL et al. Correlation between complicated diverticulitis and visceral fat. J Korean Med Sci. 2011;26(10):1339-1343.
  14. Strate LL, Liu YL, Aldoori WH et al. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology. 2009;136(1):115-122.
  15. Kopylov U, Ben-Horin S, Lahat A, Segev S. Obesity, metabolic syndrome and the risk of development of colonic diverticulosis. Digestion. 2012;86(3):201-205.
  16. Strate LL, Liu YL, Aldoori WH et al. Physical activity decreases diverticular complications. Am J Gastroenterol. 2009;104(5):1221-1230. doi: 10.1038/ajg.2009.121.
  17. Ballinger A. Adverse effects of non-steroidal anti-inflammatory drugs on the colon. Curr Gastroentrol Rep. 2008;10(5):485-489.
  18. Cologne KG, Skiada D, Beale E, Inaba K, Senagore AJ, Demetriades D. Effects of diabetes mellitus in patients presenting with diverticulitis: clinical correlations and disease characteristics in more than 1,000 patients. J Trauma Acute CareSurg. 2014;76(3):704-709. doi: 10.1097/ta.0000000000000128.
  19. Park HC, Kim BS, Lee K, Kim MJ, Lee BH. Risk factors for recurrence of right colonic uncomplicated diverticulitis after first attack. Int J Colorectal Dis. 2014;29(10):1217-1222. doi: 10.1007/s00384-014-1941-8.
  20. Kechagias A, Rautio T, Kechagias G, Mäkelä J. The role of C-reactive protein in the prediction of the clinical severity of acute diverticulitis. Am Surg. 2014;80(4):391-395.
  21. Daniels L, Budding AE, de Korte N, Eck A, Bogaards JA, Stockmann HB, Consten EC, Savelkoul PH, Boermeester MA. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur J Clin Microbiol Infect Dis. 2014;33(11):1927-1936. doi: 10.1007/s10096-014-2162-3.
  22. Tursi A, Elisei W, Picchio M, Brandimarte G. Increased faecal calprotectin predicts recurrence of colonic diverticulitis. Int J Colorectal Dis. 2014;29(8):931-935. doi: 10.1007/s00384-014-1884-0.
  23. Ambrosetti P, Gervaz A. Fossung-Wiblishauser Sigmoid diverticulitis in 2011: many questions; few answer. Colorectal Dis. 2012;14(8):e439-e446. doi: 10.1111/j.1463-1318.2012.03026.x.
  24. Lecleire S, Nahon S, Alatawi A, Antonietti M, Chaput U, Di-Fiore A, Alhameedi R, Marteau P, Ducrotté P, Dray X. Diagnostic impact of routine colonoscopy following acute diverticulitis: A multicenter study in 808 patients and controls. United Eur Gastroenterol J. 2014;2(4):301-306. doi: 10.1177/2050640614541765.
  25. Aldoori WH, Giovannucci EL, Rockett HR Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr. 1998;128:714-719.
  26. «Здоровая пища и питание женщин и их семей.» Рекомендации ВОЗ, 2002, 194 стр., EUR 01/5028597, оригинал: неотредактированный английский
  27. Hermann J, Brown В, Heintz S. Impact of а nutrition promotion program on dietary behaviors, dietary intake, and health measures in adults over fifty-five years of age. J Nutr Elderly. 2000;19(3): 1-14.
  28. Потемкина Р.А. Физическая активность. Методические рекомендации. М.: ГНИЦ профилактической медицины; 2012:36.
  29. Гинзбург М.М. Отчет об опыте применения препарата Мукофальк в комплексной терапии у пациентов с ожирением и метаболическим синдромом. Самара: НИИ диетологии и диетотерапии; 2010.
  30. Комиссаренко И.А., Левченко С.В., Гудкова Р.Б., Сильвестрова С.Ю. Эффекты длительного применения псиллиума при лечении больных с дивертикулярной болезнью толстой кишки. Клинические перспективы гастроэнтерологии и гепатологии. 2014;3:29-36.
  31. Gatta L, Vakil N, Vaira D et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol. 2010;44(2): 113-119. doi: 10.1097/mcg.0b013e3181a15864.
  32. Gross V. Aminosalicylates. Dig Dis. 2012;30(1):92-99. doi: 10.1159/000335906.
  33. Tursi A. New physiopathological and therapeutic approaches to diverticular disease: an update. Expert Opin Pharmacother. 2014;15(7):1005-1017. doi: 10.1517/14656566.2014.903922.
  34. Raskin JB, Kamm MA, Jamal MM, Márquez J, Melzer E, Schoen RE, Szalóki T, Barrett K, Streck P. Mesalamine Does Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials. Gastroenterology. 2014 pii: S0016-5085(14)00900-7. doi: 10.1053/j.gastro.2014.07.004.
  35. Lanas A, Ponce J, Bignamini A, Mearin F. One year intermittent rifaximin plus fibers supplementation vs. fibers supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig Liver Dis. 2013;45(2):104-109. doi: 10.1016/j.dld.2012.09.006.
  36. Iosca N, Ferrieri A. The rifaximin therapy and prophylaxis of episodes of acute diverticulitis. Recenti Prog Med. 1993;84(1):49-53.
  37. Tursi A, Elisei W, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, Maiorano M, Penna A, Lecca PG, Brandimarte G. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence. Eur Rev Med Pharmacol Sci. 2013;17(3):342-348.
  38. Dughera L, Serra AM, Battaglia E, Tibaudi D, Navino M, Emanuelli G. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol. 2004;50(2):149-153.
  39. Weisberger L, Jamieson B. Clinical inquiries: How can you help prevent a recurrence of diverticulitis? Fam Pract. 2009;58(7):381-382.
  40. Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci. 2011;56(11):3112-3121. doi: 10.1007/s10620-011-1731-x.
  41. Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis — a prospective randomized study. Int J Colorectal Dis. 2014;29(3):387-393. doi: 10.1007/s00384-013-1807-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies